Drug

AbbVie's Dual‑Targeting ABBV‑466 Outperforms Both Monotherapies in Crohn's Disease – Higher Endoscopic Remission Rates at Week 12 in TARGET‑CD Study
AbbVieClinical trial results

AbbVie’s Dual‑Targeting ABBV‑466 Outperforms Both Monotherapies in Crohn’s Disease – Higher Endoscopic Remission Rates at Week 12 in TARGET‑CD Study

AbbVie Inc. (NYSE: ABBV) announced that its investigational ABBV‑466, a novel dual‑targeting therapy against IL‑23 p19 and integrin α4β7, demonstrated higher rates of endoscopic remission at Week 12 than either…

Mabwell to Present Phase II Data for Nectin‑4 ADC 9MW2821 at ESMO 2026 – 30.0% ORR in Post‑TOP1i‑ADC Triple‑Negative Breast Cancer, Headlining Four Phase III Programs

Mabwell to Present Phase II Data for Nectin‑4 ADC 9MW2821 at ESMO 2026 – 30.0% ORR in Post‑TOP1i‑ADC Triple‑Negative Breast Cancer, Headlining Four Phase III Programs

EMA's CHMP Backs Flexible Dosing for Regeneron's Libtayo – Every‑Six‑Week 700 mg Regimen and Shortened Infusion Options Across All Approved PD‑1 Indications

EMA’s CHMP Backs Flexible Dosing for Regeneron’s Libtayo – Every‑Six‑Week 700 mg Regimen and Shortened Infusion Options Across All Approved PD‑1 Indications

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
RiboLife’s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform
Rare / orphan disease drugsRibo Life Science

RiboLife’s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform

Astellas China Secures GBA Approval for First‑in‑Class Fezolinetant (VEOZA)
Astellas PharmaProduct approvals

Astellas China Secures GBA Approval for First‑in‑Class Fezolinetant (VEOZA)

Sanofi Q3 2025 Results: 7 % Revenue Growth, Dupixent Drives Pharma Upswing
Finanical ReportsNASDAQ: SNY

Sanofi Q3 2025 Results: 7 % Revenue Growth, Dupixent Drives Pharma Upswing

Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans
Circode BioRare / orphan disease drugs

Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans

Show More